Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccination

  1. Joseph J Campo  Is a corresponding author
  2. Timothy Q Le
  3. Jozelyn V Pablo
  4. Christopher Hung
  5. Andy A Teng
  6. Hervé Tettelin
  7. Andrea Tate
  8. William P Hanage
  9. Mark R Alderson
  10. Xiaowu Liang
  11. Richard Malley
  12. Marc Lipsitch
  13. Nicholas J Croucher  Is a corresponding author
  1. Antigen Discovery Inc, United States
  2. University of Maryland, United States
  3. PATH, United States
  4. Harvard TH Chan School of Public Health, United States
  5. Boston Children's Hospital, United States
  6. Imperial College London, United Kingdom

Abstract

Pneumococcal whole cell vaccines (WCVs) could cost-effectively protect against a greater strain diversity than current capsule-based vaccines. Immunoglobulin G (IgG) responses to a WCV were characterised by applying longitudinally-sampled sera, available from 35 adult placebo-controlled phase I trial participants, to a panproteome microarray. Despite individuals maintaining distinctive antibody 'fingerprints', responses were consistent across vaccinated cohorts. Seventy-two functionally distinct proteins were associated with WCV-induced increases in IgG binding. These shared characteristics with naturally immunogenic proteins, being enriched for transporters and cell wall metabolism enzymes, likely unusually exposed on the unencapsulated WCV's surface. Vaccine-induced responses were specific to variants of the diverse PclA, PspC and ZmpB proteins, whereas PspA- and ZmpA-induced antibodies recognised a broader set of alleles. Temporal variation in IgG levels suggested a mixture of anamnestic and novel responses. These reproducible increases in IgG binding a limited, but functionally diverse, set of conserved proteins indicate WCV could provide species-wide immunity.

Data availability

Sequencing data have been deposited in the ENA under accession code ERS2169631. Proteome array data analysed in this study is available as source data files for figures one and two.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Joseph J Campo

    Antigen Discovery Inc, Irvine, United States
    For correspondence
    jcampo@antigendiscovery.com
    Competing interests
    Joseph J Campo, is an employee of Antigen Discovery, Inc.
  2. Timothy Q Le

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Timothy Q Le, is an employee of Antigen Discovery, Inc.
  3. Jozelyn V Pablo

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Jozelyn V Pablo, is an employee of Antigen Discovery, Inc.
  4. Christopher Hung

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Christopher Hung, is an employee of Antigen Discovery, Inc.
  5. Andy A Teng

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Andy A Teng, is an employee of Antigen Discovery, Inc.
  6. Hervé Tettelin

    Institute for Genome Sciences, School of Medicine, University of Maryland, Baltimore, United States
    Competing interests
    No competing interests declared.
  7. Andrea Tate

    PATH, Seattle, United States
    Competing interests
    No competing interests declared.
  8. William P Hanage

    Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, United States
    Competing interests
    William P Hanage, work on this project was supported by consulting payments from Antigen Discovery, Inc.
  9. Mark R Alderson

    PATH, Seattle, United States
    Competing interests
    No competing interests declared.
  10. Xiaowu Liang

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Xiaowu Liang, is an employee of Antigen Discovery, Inc. and has an equity interest in Antigen Discovery, Inc.
  11. Richard Malley

    Boston Children's Hospital, Boston, United States
    Competing interests
    Richard Malley, has received honoraria or consulting fees from Merck and Affinivax, and has received research grants through his institution from PATH, the Bill and Melinda Gates Foundation, and Pfizer.
  12. Marc Lipsitch

    Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, United States
    Competing interests
    Marc Lipsitch, Reviewing editor, eLife, work on this project was supported by consulting payments from Antigen Discovery, Inc, has received honoraria or consulting fees from Pfizer, Affinivax, and Merck, and has received research grants through his institution from Pfizer and PATH.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1504-9213
  13. Nicholas J Croucher

    Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom
    For correspondence
    n.croucher@imperial.ac.uk
    Competing interests
    Nicholas J Croucher, work on this project was supported by consulting payments from Antigen Discovery, Inc.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6303-8768

Funding

Bill and Melinda Gates Foundation

  • Joseph J Campo
  • Timothy Q Le
  • Jozelyn V Pablo
  • Christopher Hung
  • Andy A Teng

National Institutes of Health (R01AI066304)

  • Marc Lipsitch

Wellcome (104169/Z/14/Z)

  • Nicholas J Croucher

Royal Society (104169/Z/14/Z)

  • Nicholas J Croucher

PATH

  • Andrea Tate
  • Mark R Alderson

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Bavesh D Kana, University of the Witwatersrand, South Africa

Ethics

Human subjects: The VAC-002 phase 1 study (ClinicalTrials.gov identifier: NCT01537185) was reviewed and approved by the Western Institutional Review Board and conducted in compliance with the study protocol, international standards of Good Clinical Practice and the Declaration of Helsinki. Participants were healthy adults aged 18 to 40 years at the time of consent, and had no evidence of chronic health issues, and nor any history of invasive pneumococcal disease or pneumococcal vaccination.

Version history

  1. Received: March 27, 2018
  2. Accepted: December 25, 2018
  3. Accepted Manuscript published: December 28, 2018 (version 1)
  4. Version of Record published: January 23, 2019 (version 2)

Copyright

© 2018, Campo et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,448
    views
  • 242
    downloads
  • 22
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Joseph J Campo
  2. Timothy Q Le
  3. Jozelyn V Pablo
  4. Christopher Hung
  5. Andy A Teng
  6. Hervé Tettelin
  7. Andrea Tate
  8. William P Hanage
  9. Mark R Alderson
  10. Xiaowu Liang
  11. Richard Malley
  12. Marc Lipsitch
  13. Nicholas J Croucher
(2018)
Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccination
eLife 7:e37015.
https://doi.org/10.7554/eLife.37015

Share this article

https://doi.org/10.7554/eLife.37015

Further reading

    1. Evolutionary Biology
    2. Immunology and Inflammation
    Mark S Lee, Peter J Tuohy ... Michael S Kuhns
    Research Advance

    CD4+ T cell activation is driven by five-module receptor complexes. The T cell receptor (TCR) is the receptor module that binds composite surfaces of peptide antigens embedded within MHCII molecules (pMHCII). It associates with three signaling modules (CD3γε, CD3δε, and CD3ζζ) to form TCR-CD3 complexes. CD4 is the coreceptor module. It reciprocally associates with TCR-CD3-pMHCII assemblies on the outside of a CD4+ T cells and with the Src kinase, LCK, on the inside. Previously, we reported that the CD4 transmembrane GGXXG and cytoplasmic juxtamembrane (C/F)CV+C motifs found in eutherian (placental mammal) CD4 have constituent residues that evolved under purifying selection (Lee et al., 2022). Expressing mutants of these motifs together in T cell hybridomas increased CD4-LCK association but reduced CD3ζ, ZAP70, and PLCγ1 phosphorylation levels, as well as IL-2 production, in response to agonist pMHCII. Because these mutants preferentially localized CD4-LCK pairs to non-raft membrane fractions, one explanation for our results was that they impaired proximal signaling by sequestering LCK away from TCR-CD3. An alternative hypothesis is that the mutations directly impacted signaling because the motifs normally play an LCK-independent role in signaling. The goal of this study was to discriminate between these possibilities. Using T cell hybridomas, our results indicate that: intracellular CD4-LCK interactions are not necessary for pMHCII-specific signal initiation; the GGXXG and (C/F)CV+C motifs are key determinants of CD4-mediated pMHCII-specific signal amplification; the GGXXG and (C/F)CV+C motifs exert their functions independently of direct CD4-LCK association. These data provide a mechanistic explanation for why residues within these motifs are under purifying selection in jawed vertebrates. The results are also important to consider for biomimetic engineering of synthetic receptors.

    1. Genetics and Genomics
    2. Immunology and Inflammation
    Jean-David Larouche, Céline M Laumont ... Claude Perreault
    Research Article

    Transposable elements (TEs) are repetitive sequences representing ~45% of the human and mouse genomes and are highly expressed by medullary thymic epithelial cells (mTECs). In this study, we investigated the role of TEs on T-cell development in the thymus. We performed multiomic analyses of TEs in human and mouse thymic cells to elucidate their role in T-cell development. We report that TE expression in the human thymus is high and shows extensive age- and cell lineage-related variations. TE expression correlates with multiple transcription factors in all cell types of the human thymus. Two cell types express particularly broad TE repertoires: mTECs and plasmacytoid dendritic cells (pDCs). In mTECs, transcriptomic data suggest that TEs interact with transcription factors essential for mTEC development and function (e.g., PAX1 and REL), and immunopeptidomic data showed that TEs generate MHC-I-associated peptides implicated in thymocyte education. Notably, AIRE, FEZF2, and CHD4 regulate small yet non-redundant sets of TEs in murine mTECs. Human thymic pDCs homogenously express large numbers of TEs that likely form dsRNA, which can activate innate immune receptors, potentially explaining why thymic pDCs constitutively secrete IFN ɑ/β. This study highlights the diversity of interactions between TEs and the adaptive immune system. TEs are genetic parasites, and the two thymic cell types most affected by TEs (mTEcs and pDCs) are essential to establishing central T-cell tolerance. Therefore, we propose that orchestrating TE expression in thymic cells is critical to prevent autoimmunity in vertebrates.